CBLL · Ceribell, Inc.
$23.33
+0.08 (+0.34%)
At close · Aug 14
Market Cap
$895.36M
Shares
38.38M
Ceribell, Inc. Earnings Call Transcripts
Every quarterly earnings call for Ceribell, Inc. (CBLL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲48.1%
$17.20M
−$10.42M
'24 Q3
24-11-12
·
$18.53M
−$12.58M
'24 Q4
25-02-25
▲42.3%
$20.49M
−$12.78M
'25 Q1
25-05-08
▲38.4%
$21.20M
−$13.64M
'25 Q2
25-08-05
▲31.4%
$22.59M
−$13.46M
'25 Q3
25-11-04
▲33.7%
$24.78M
−$13.53M
'25 Q4
26-02-24
▲29.3%
$26.49M
−$19.74M
'26 Q1
26-05-11
LATEST
▲32.5%
$28.10M
−$19.27M
'26 Q2
26-08-10
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
Ceribell Q2 2026 Earnings Call
Revenue
$28.10M
▲ 32.5% YoY Diluted EPS
$-0.51
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-11
Ceribell, Inc. Q1 FY2026 Earnings Call
Confident tone
Headband utilization and same-store growth
Neonate and pediatric product launches
Gross margin and profitability outlook
Revenue
$26.49M
▲ 29.3% YoY Diluted EPS
$-0.52
Gross margin
87.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Ceribell, Inc. Q4 FY2025 Earnings Call
Confident tone
Neonate and pediatric FDA clearance
Standard of care / point-of-care EEG vision
VA / FedRAMP opportunity
Revenue
$24.78M*
▲ 33.7% YoY Gross margin
87.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ceribell, Inc. Q3 FY2025 Earnings Call
Confident tone
Revenue growth and guidance raise
Active account expansion
Standard of care / category leadership vision
Revenue
$22.59M
▲ 31.4% YoY Diluted EPS
$-0.37
Gross margin
88.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ceribell, Inc. Q2 FY2025 Earnings Call
Confident tone
Delirium product development
Commercial expansion and territory build-out
Neonate / NICU pilot and expansion
Revenue
$21.20M
▲ 38.4% YoY Diluted EPS
$-0.38
Gross margin
88.1%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Ceribell, Inc. Q1 FY2025 Earnings Call
Confident tone
Gross Margin and Pricing
Pediatric Clarity Clearance
Commercial Expansion
Revenue
$20.49M
▲ 42.3% YoY Diluted EPS
$-0.36
Gross margin
87.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Ceribell, Inc. Q4 FY2024 Earnings Call
Confident tone
Clinical impact and patient stories
Revenue growth and financial performance
Account acquisition and sales force expansion
Revenue
$18.53M*
Gross margin
87.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Ceribell, Inc. Q3 FY2024 Earnings Call
Revenue
$17.20M
▲ 48.1% YoY Diluted EPS
$-1.85
Gross margin
87.3%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–10 of 10 earnings calls
Key facts
CIK
1861107
CUSIP
15678C102
13F (30d)
121 filings
116 filers
Visit website
Investor relations